A tumor cell targeting surface-enhanced Raman scattering (SERS) probe has been successfully synthesized by using p-mercaptobenzoic acid (pMBA) as both the SERS reporter and the conjugation agent for attaching transferrin molecules, which shows experimentally the targeting ability for transferrin receptor-overexpressed HeLa cells and exhibits strong SERS signals when being incubated inside cells. To prove that the uptake of such a SERS probe is through a Tf-receptor-mediated endocytosis process, two control experiments: (1) HeLa cells being incubated with the probe at 4 degrees C and (2) HeLa cells being pre-blocked with free transferrin at 37 degrees C, were employed. The difference of SERS intensity between the transferrin-overexpressed HeLa cells and transferrin-pre-blocked HeLa cells indicates that the probe has the potential to selectively target tumor cells.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: